Hepatic metastasis from bile duct cancer of the ampulla is effectively controlled by multidisciplinary treatment including S-1, gemcitabine and bevacizumab: A case report

Tokunaga,Yukihiko; Kawasaki,Toshihiko; Sasaki,Hirokazu; Matsueda,Shigeki; Saito,Tohru

doi:10.3892/ol_00000084

Hepatic metastasis from bile duct cancer of the ampulla is effectively controlled by multidisciplinary treatment including S-1, gemcitabine and bevacizumab: A case report

Authors:
- Yukihiko Tokunaga
- Toshihiko Kawasaki
- Hirokazu Sasaki
- Shigeki Matsueda
- Tohru Saito
View Affiliations

Affiliations: Department of Surgery, Osaka North Japan Post Hospital, Osaka 530-8798, Japan. tokunagay@usay6.com
Published online on: May 1, 2010 https://doi.org/10.3892/ol_00000084
Pages: 481-484

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The liver is the most common site for recurrent metastases from bile duct cancer (BDC) in the ampullary area. However, the optimal chemotherapy regimen for recurrent hepatic metastases has not yet been established. An oral combined fluoropyrimidine drug, S-1 (tegafur, gimeracil and oteracil), has recently been introduced alone or in combination with gemcitabine for BDC. A 67-year-old man underwent a pancreaticoduodenectomy (PD) for early stage distal BDC in the ampullary area. A small hepatic metastasis developed 8 months after the PD. Combined chemotherapy of S-1 (80 mg/m2) and gemcitabine (1,000 mg/m2) was started after radiofrequency ablation (RFA) of the hepatic tumor. Although complete response was achieved and maintained for 4 months with chemotherapy, there was regrowth of the tumor. We performed hepatic segmentectomy for radical treatment. Fourteen months after the hepatectomy, metastasis developed again in the remnant liver. Bevacizumab was added to the combination chemotherapy with S-1 and gemcitabine, since the cancer seemed resistant to the chemotherapy alone. The patient has been well managed for 3 years by a multidisciplinary treatment with surgery, RFA and the combination chemotherapy on an outpatient basis. This case indicates that distal BDC even in an early stage has a more malignant potential than anticipated. The multidisciplinary treatment including surgery, RFA and combination chemotherapy of S-1, gemcitabine and bevacizumab was effective for BDC with hepatic metastasis. This chemotherapy is feasible on an outpatient basis and may be one of the treatment options for metastatic BDC.

View Figures

View References

1	Nakeeb A, Pitt HA, Sohn TA, Coleman J, Abrams RA, Piantadosi S, Hruban RH, Lillemoe KD, Yeo CJ and Cameron JL: Cholangiocarcinoma: a spectrum of intrahepatic, perihilar and distal tumors. Ann Surg. 224:463–475. 1996. View Article : Google Scholar : PubMed/NCBI
2	Fong Y, Blumgart LH, Lin E, Fortner JG and Brennan MF: Outcome of treatment for distal bile duct cancer. Br J Surg. 83:1712–1715. 1996. View Article : Google Scholar : PubMed/NCBI
3	Bortolasi L, Burgart LJ, Tsiotos GG, Lugue-De Leon E and Sarr MG: Adenocarcinoma of the distal bile duct (a clinicopathologic outcome analysis after curative resection). Dig Surg. 17:36–41. 2000.PubMed/NCBI
4	Nagorney DM, Donohue JH, Farnell MB, Schleck CD and Ilstrup DM: Outcome after curative resection of cholangiocarcinoma. Arch Surg. 128:871–879. 1993. View Article : Google Scholar : PubMed/NCBI
5	Kayahara M, Nagakawa T, Ueno K, Ohta T, Tsukioka Y and Miyazaki I: Surgical strategy for carcinoma of the pancreas head area based on clinicopathologic analysis of nodal involvement and plexus invasion. Surgery. 117:616–623. 1995. View Article : Google Scholar : PubMed/NCBI
6	Shirasaka T, Shimamoto Y, Ohshimo H, Yamaguchi H, Kato T, Yonekura K and Fukushima M: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective toxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 7:548–557. 1996. View Article : Google Scholar : PubMed/NCBI
7	Okusaka T, Funakoshi A, Furuse J, Boku N, Yamao K, Ohkawa S and Saito H: A late phase II study of S-1 for metastatic pancreatic cancer. Cancer Chemother Pharmacol. 61:615–621. 2008. View Article : Google Scholar : PubMed/NCBI
8	Ueno H, Okusaka T, Ikeda M, Takezako Y and Morizane C: Phase II study of S-1 in patients with advanced biliary tract cancer. Br J Cancer. 15:1769–1774. 2004. View Article : Google Scholar : PubMed/NCBI
9	Lin MH, Chen JS, Chen HH and Su WC: A phase II trial of gemcitabine in the treatment of advanced bile duct and periampullary carcinoma. Chemotherapy. 49:154–158. 2003. View Article : Google Scholar : PubMed/NCBI
10	Okusaka T, Ishii H, Funakoshi A, Yamao K, Ohkawa S, Saiot S, Saito H and Tsuyuguchi T: Phase II trial of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol. 57:647–653. 2006. View Article : Google Scholar : PubMed/NCBI
11	Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R and Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Eng J Med. 350:2335–2342. 2004. View Article : Google Scholar : PubMed/NCBI
12	Todoroki T, Koike N, Morishita Y, Kawamoto T, Ohkochi N, Shoda J, Fukuda Y and Takahashi H: Patterns and failure after curative resections of carcinoma of the ampulla of Vater. Ann Surg Oncol. 10:1176–1183. 2003. View Article : Google Scholar : PubMed/NCBI
13	Bhuiya MR, Nimura Y, Kamiya K, Kondo S, Fukata S, Hayakawa N and Shionoya S: Clinicopathologic studies in perineural invasion of bile duct carcinoma. Ann Surg. 215:344–349. 1992. View Article : Google Scholar : PubMed/NCBI
14	Chan C, Herrera MF, De la Garza L, Quantanilla-Martinez L, Vargas-Vorackova F, Richaud-Patin Y, Llorente L, Uscanga L, Robles-Diaz G and Leon E: Clinical behavior and prognostic factors of periampullary adenocarcinoma. Ann Surg. 222:632–637. 1995. View Article : Google Scholar : PubMed/NCBI
15	Woo SM, Ryu JK, Lee SH, Yoo JW, Park JK, Kim YT, Jang JY, Kim SW, Kang GH and Yoon YB: Recurrence and prognostic factors of ampullary carcinoma after radical resection: comparison with distal extrahepatic cholangiocarcinoma. Ann Surg Oncol. 14:3195–3201. 2007. View Article : Google Scholar
16	Takada T, Nimura Y, Katoh H, Nagakawa T, Nakayama T, Matsushiro T, Amano H and Wada K: Prospective randomized trial of 5-fluorouracil, doxorubicin and mitomycin C for non-resectable pancreatic and biliary carcinoma: multicenter randomized trial. Hepatogastroenterology. 45:2020–2026. 1998.
17	Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H, Nagakawa T and Nakayama T: Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 95:1685–1695. 2002. View Article : Google Scholar
18	Nakamura K, Yamaguchi T, Ishihara T, Sudo K, Kato H and Saisho H: Phase II trail of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer. 94:1575–1579. 2006.PubMed/NCBI
19	Kindler HL, Niedzwiecki D, Hollis D, Martin EW, Schilsky RL and Goldberg RM: A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced panreatic cancer (PC): a preliminary analysis of Cancer and Leukemia Group B (CALGB) 80303. In: ASCO Gastrointestinal Cancer Symposium. abs. 108. 2007